Abstract: A heat exchanger includes a sensor grid with sensor leads extending through tube restraints for heat exchange tubes in the heat exchanger. The tube restraint includes a body having a plurality of tube openings defined therein with each tube opening receiving one heat exchange tube of the set of heat exchange tubes therethrough. The body also includes a sensor lead opening defined therein to receive a sensor lead therethrough. Each tube opening has a larger dimension than the sensor lead opening. The sensor grid is installed during manufacture rather than in the field, allowing the sensor grid to be on outermost and inner sets of heat exchange tubes in the heat exchanger.

Abstract: A heat exchanger includes a sensor grid with sensor leads extending through tube restraints for heat exchange tubes in the heat exchanger. The tube restraint includes a body having a plurality of tube openings defined therein with each tube opening receiving one heat exchange tube of the set of heat exchange tubes therethrough. The body also includes a sensor lead opening defined therein to receive a sensor lead therethrough. Each tube opening has a larger dimension than the sensor lead opening. The sensor grid is installed during manufacture rather than in the field, allowing the sensor grid to be on outermost and inner sets of hea exchange tubes in the heat exchanger.

Abstract: The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.

Abstract: The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.

Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described.

Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described.

Abstract: A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof is described.